Roche: joins forces with US drugmaker for COVID treatment
(CercleFinance.com) - Roche said on Thursday that it will team up with US biopharmaceutical firm Atea to develop a potential oral treatment for COVID-19 patients.
The two companies said they are joining forces to develop, manufacture and distribute Atea's investigational antiviral AT-527, which blocks the RNA polymerase enzyme needed for viral replication.
The drug is currently being studied in a phase 2 clinical trial for hospitalised patients with moderate COVID-19, with a phase 3 trial expected to start in early 2021 in outpatients.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The two companies said they are joining forces to develop, manufacture and distribute Atea's investigational antiviral AT-527, which blocks the RNA polymerase enzyme needed for viral replication.
The drug is currently being studied in a phase 2 clinical trial for hospitalised patients with moderate COVID-19, with a phase 3 trial expected to start in early 2021 in outpatients.
Copyright (c) 2020 CercleFinance.com. All rights reserved.